Data / Form D filings / PTC THERAPEUTICS, INC.
PTC THERAPEUTICS, INC.: Form D filings
PTC THERAPEUTICS, INC., a biotechnology company in South Plainfield, NJ, filed 10 Form D notices with the SEC between 2009 and 2023. The latest, on May 8, 2023, reports $35.9 million sold of a $35.9 million offering to 40 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 100 CORPORATE COURT, South Plainfield, NJ, 07080
- Phone
- (908) 222-7000
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1070081
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 8, 2023 | New notice | $35,897,425 | $35,897,425 | 40 | Apr 10, 2023 | sec.gov | |
| Jun 12, 2020 | New notice | $41,905,000 | $41,905,000 | 38 | May 29, 2020 | sec.gov | |
| May 14, 2020 | New notice | $140,949,151 | $140,949,151 | 57 | Apr 29, 2020 | sec.gov | |
| Sep 5, 2018 | New notice | $150,000,000 | $150,000,000 | 52 | Aug 23, 2018 | sec.gov | |
| May 15, 2013 | New notice | $4,500,000 | $4,500,000 | 1 | May 14, 2013 | sec.gov | |
| Mar 21, 2013 | New notice | $59,999,448 | $59,999,448 | 32 | Mar 7, 2013 | sec.gov | |
| Feb 12, 2013 | New notice | $16,100,100 | $2,000,100 | $14,100,000 | 25 | Jan 29, 2013 | sec.gov |
| Jun 13, 2012 | New notice | $40,000,000 | $22,950,840 | $17,049,160 | 27 | May 29, 2012 | sec.gov |
| Dec 22, 2009 | New notice | $50,300,000 | $25,150,064 | $25,149,936 | 21 | Dec 22, 2009 | sec.gov |
| Oct 7, 2009 | New notice | $1,000,000 | $0 | $1,000,000 | 2 | Sep 22, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Stepanie S. Okey | Director | |
| Michael B. Schmertzler | Director | |
| Matthew B. Klein, M.D. | Executive Officer, Director | |
| Eric E. Pauwels | Executive Officer | |
| Alethia P. Young | Director | |
| Neil B. Almstead, Ph.D | Executive Officer | |
| Glenn D. Steele Jr., M.D., Ph.D. | Director | |
| David P. Southwell | Director | |
| Emily E. Hill | Executive Officer | |
| Jerome B. Zeldis, M.D., Ph.D. | Director | |
| Mark E. Boulding | Executive Officer | |
| Christine E. Utter | Executive Officer | |
| Allan D. Jacobson, Ph.D. | Director | |
| Emma B. Reeve | Director | |
| Mary D. Smith | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of May 8, 2023 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what PTC THERAPEUTICS, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.